Literature DB >> 11927969

The role of thymidine phosphorylase and thrombospondin-1 in angiogenesis and progression of intrahepatic cholangiocarcinoma.

Shin-ichi Aishima1, Ken-ichi Taguchi, Keishi Sugimachi, Yoshiki Asayama, Hidehiro Nishi, Mitsuo Shimada, Keizo Sugimachi, Masazumi Tsuneyoshi.   

Abstract

Thymidine phosphorylase (TP), an important regulator of angiogenesis, is correlated with progression, metastasis, and prognosis in various types of tumor. In contrast, both positive and negative effects of thrombospondin-1 (TSP-1) on angiogenesis have been reported. In the present study, we examined the expression of TP and TSP-1 in carcinoma cells in 67 primary intrahepatic cholangiocarcinomas (ICCs) immunohistochemically and its correlation with angiogenesis, clinicopathological features, and prognosis. Twenty-six (38.8%) cases were classified as exhibiting positive TP expression. TP expression showed a significant correlation with vascular invasion, lymphatic permeation, perineural invasion, and lymph node metastasis. Thirty-four (50.7%) cases were classified as exhibiting positive TSP-1 expression. TSP-1 expression was significantly correlated with only lymphatic permeation. The microvessel count in positive TP expression cases was significantly higher than that in negative cases. In contrast, the microvessel count in negative TSP-1 expression cases was significantly higher than that in positive cases. Survival in patients who were positive for both TP and TSP-1 expression was significantly poor. Our results suggest that the increased TP expression and decreased TSP-1 expression contribute to angiogenesis, but that the role of angiogenesis in ICC is not closely related to tumor aggressiveness. The TP and TSP-1 expression in ICC may enhance tumor aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927969     DOI: 10.1177/106689690201000108

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  10 in total

1.  Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.

Authors:  Jongkonnee Thanasai; Temduang Limpaiboon; Patcharee Jearanaikoon; Banchob Sripa; Chawalit Pairojkul; Srisurang Tantimavanich; Masanao Miwa
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

2.  Amplification of D22S283 as a favorable prognostic indicator in liver fluke related cholangiocarcinoma.

Authors:  Jongkonnee Thanasai; Temduang Limpaiboon; Patcharee Jearanaikoon; Vajarabhongsa Bhudhisawasdi; Narong Khuntikeo; Banchob Sripa; Masanao Miwa
Journal:  World J Gastroenterol       Date:  2006-07-21       Impact factor: 5.742

Review 3.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

Review 4.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

Review 5.  Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

Authors:  Alphonse E Sirica; Catherine I Dumur; Deanna J W Campbell; Jorge A Almenara; Olorunseun O Ogunwobi; Jennifer L Dewitt
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11       Impact factor: 11.382

Review 6.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

7.  Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.

Authors:  Shengjie Sun; Huiyu Dong; Tao Yan; Junchen Li; Bianjiang Liu; Pengfei Shao; Jie Li; Chao Liang
Journal:  BMC Med Genet       Date:  2020-06-29       Impact factor: 2.103

8.  Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.

Authors:  Shuichi Aoki; Koetsu Inoue; Sebastian Klein; Stefan Halvorsen; Jiang Chen; Aya Matsui; Mohammad R Nikmaneshi; Shuji Kitahara; Tai Hato; Xianfeng Chen; Kazumichi Kawakubo; Hadi T Nia; Ivy Chen; Daniel H Schanne; Emilie Mamessier; Kohei Shigeta; Hiroto Kikuchi; Rakesh R Ramjiawan; Tyge Ce Schmidt; Masaaki Iwasaki; Thomas Yau; Theodore S Hong; Alexander Quaas; Patrick S Plum; Simona Dima; Irinel Popescu; Nabeel Bardeesy; Lance L Munn; Mitesh J Borad; Slim Sassi; Rakesh K Jain; Andrew X Zhu; Dan G Duda
Journal:  Gut       Date:  2021-01-11       Impact factor: 31.793

9.  ERCC1 Can Be a Prognostic Factor in Hilar Cholangiocarcinoma and Extrahepatic Bile Duct Cancer, But Not in Intrahepatic Cholangiocarcinoma.

Authors:  Kyun Woo Park; Eun-Seon Jung; Dong-Gu Kim; Young-Kyung Yoo; Tae-Ho Hong; In Seok Lee; Yoon Ho Koh; Ji-Hoon Kim; Myung Ah Lee
Journal:  Cancer Res Treat       Date:  2013-03-31       Impact factor: 4.679

10.  MicroRNA‑218 inhibits tumor angiogenesis of human renal cell carcinoma by targeting GAB2.

Authors:  Lijun Mu; Bing Guan; Juanhua Tian; Xiang Li; Qingzhi Long; Meiyu Wang; Wen Wang; Junjun She; Xudong Li; Dapeng Wu; Yuefeng Du
Journal:  Oncol Rep       Date:  2020-09-08       Impact factor: 4.136

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.